Abstract

The Dana-Farber Cancer Institute is an independent, federally dcsignated, Comprehensive Cancer Center affiliated with the Harvard Medical School.
The aims of the Institute can be summarized as follows: (a) to develop and maintain clinical and laboratory research programs of high quality related to the biology, cause and prevention, diagnosis and treatment of cancer; (b) to provide total care for cancer patients on an interdisciplinary basis and in association with neighboring institutions; c) to serve as the major cancer center in the Harvard-Longwood medical area and to play a leadership role for cancer research and patient care in New England providing expertise in cancer diagnosis and treatment; (d) to add to the total oncology resources of the medical community in terms of available staff, facilities and expertise; (e) to participate in the teaching and training of medical students, house staff, fellows and graduate students and in the continuing education of practicing physicians and other health professionals, and to provide post-doctoral research training. To maintain these activities, the present application requests renewal of the Institute's Cancer Core Support Grant.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-29
Application #
3101213
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-12-01
Project End
1995-01-31
Budget Start
1992-02-13
Budget End
1993-01-31
Support Year
29
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917

Showing the most recent 10 out of 411 publications